SecBot SecBot
S-3 ·Filed Jun 26, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001493152-26-030346
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Monitor for immediate selling by insiders (Ting Yang, Lina Deng, David Lazar) which could pressure the stock. The company's lack of pipeline and going-concern status make further dilutive financing or a distressed sale likely. Traders should watch for any 8-K filings regarding strategic alternatives or additional capital raises.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.06
T+0 close · Jun 26, 2026 · via day close
Latest settled
+30.39%
T+60 · $3.99
Vs SPY
+26.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $3.06entry
  2. T+1 · 5mo ago −1.96%α −2.74% · $3.00
  3. T+5 · 4mo ago −6.86%α −8.25% · $2.85
  4. T+20 · 4mo ago −14.71%α −14.43% · $2.61
  5. T+60 · 8w ago +30.39%α +26.01% · $3.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David Lazar) to resell up to 18,864,000 shares of common stock, representing approximately 14.2% of outstanding shares. The company will not receive any proceeds. This filing comes amid a severe operational crisis: the company has discontinued all clinical development of its lead candidate Decoy20, has no active programs, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The resale registration creates significant overhang and facilitates insider selling, compounding the fundamental distress.

Key Facts

  • 18,864,000 shares registered for resale by three selling stockholders (Ting Yang, Lina Deng, David Lazar), approximately 14.2% of the 133,242,324 shares outstanding.
  • Company receives no proceeds; all proceeds go to selling stockholders.
  • Decoy20 clinical programs fully discontinued; no active clinical development programs.
  • Auditor's report includes a going-concern explanatory paragraph.
  • Change of control occurred in March 2026; new management and board in place.
  • Multiple dilutive financings in the past 18 months: June 2026 private placement ($12M), June 2025 private placement ($2.3M convertible notes), and various other offerings.

Financial Impact

Potential overhang of ~14.2% of outstanding shares; at the June 22, 2026 closing price of $3.775, the registered shares have a market value of approximately $71.2 million.

dilutionmarket capitalizationliquidity

Risk Factors

  • Insider selling from the registered shares could create sustained downward pressure.
  • Company may need to raise additional capital at distressed terms, further diluting existing shareholders.
  • Inability to secure a strategic transaction or financing could lead to delisting or bankruptcy.
  • Concentrated ownership (96.2% held by a small group after March 2026 transfer) creates governance and liquidity risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001493152-26-030346
Exhibit: ex107.htm0001493152-26-030346
Exhibit: ex5-1.htm0001493152-26-030346
Exhibit: ex23-2.htm0001493152-26-030346
Document: 0001493152-26-030346-index-headers.html0001493152-26-030346
Document: 0001493152-26-030346-index.html0001493152-26-030346
Document: 0001493152-26-030346.txt0001493152-26-030346

Track record

20 reports on INDP

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026